Presentation of squamous cell carcinoma in pre-existing cutaneous sarcoidosis

Lim, Puo Nen; Kirby, Lisa; Wylie, Grant

doi:10.1136/bcr-2020-236426

Cited by 4 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another peculiar finding presented here concerns the observed association of anti‐PD‐1 therapy with the development of disseminated thoracic SRs. Indeed, only anecdotal observations of cSCC associated with granulomatous reactions have been made, and those developed independently of any treatment 9,10 . At the same time, the fact that SRs have been described as possible irAEs of ICI for other entitites together with the close correlation between the start of ICI treatment and the detection of SRs in the present case renders immunotherapy the most likely cause of the granulomatous reactions observed here 4–8 .…”

Section: Discussionmentioning

confidence: 60%

Development of thoracic sarcoid reactions associated with complete response to anti‐PD‐1 therapy in a patient with advanced cutaneous squamous cell carcinoma

Gambichler

Philippou

Scheel

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

In patients with advanced cutaneous squamous cell carcinoma (cSCC), positive efficacy data were reported for anti‐PD‐1 antibodies. However, anti‐PD‐1 treatment is associated with a wide range of immune‐related adverse events (irAEs). Here, we report on a 78‐year‐old woman with a huge cSCC on the right cheek spanning from the temporal to the cervical region with evidence for infiltration of the parotid gland, right masseter muscle and right auditory canal. Ultrasound revealed cervical, submandibular and supraclavicular lymph node metastases on patient’s right side. On the basis of a medical hardship application, treatment with pembrolizumab was initiated. After two applications, a dramatic regression of the tumour was observed. At this point, the patient was switched to cemiplimab, which, in the meantime, had become available in Germany. After 3 months on cemiplimab, the tumour‐related ulcer on the right cheek showed almost complete regression and all previously affected lymph nodes displayed no evidence for malignancy. Thoracic computed tomography (CT) scans revealed enlarged mediastinal and bilateral hilar lymph nodes assessed as primarily reactive. Three months later, however, mediastinal and bilateral hilar lymph nodes further increased in size, accompanied by radiological alterations of the lung parenchyma. Lymph node biopsies revealed sarcoid reactions (SRs) including fibrotic non‐caseating epitheloid cell granulomas surrounded by lymphocytes. Since the patient did not display any clinical symptoms, cemiplimab treatment was continued following a 4‐week break. Three months later, CT showed significant regression of the described enlarged lymph nodes and parenchymal lung changes. Twenty months after anti‐PD‐1 treatment, the patient was still in complete remission. In conclusion, we describe, for the first time, the case of a patient with advanced cSCC who developed disseminated thoracic SRs which were associated with dramatic regression of tumour masses. Thus, as with other irAEs, development of SRs might be indicative of an anti‐tumour response to anti‐PD‐1 therapy.

show abstract

Section: Discussionmentioning

confidence: 60%

Development of thoracic sarcoid reactions associated with complete response to anti‐PD‐1 therapy in a patient with advanced cutaneous squamous cell carcinoma

Gambichler

Philippou

Scheel

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Many studies revealed an increased risk of association with skin cancers (melanoma and non-melanoma skin cancers) in patients with sarcoidosis. They can develop on previous sarcoidotic lesions or in normal skin in these patients 4. This association may be due to a dysfunction of the immune system favouring an abnormal response to cancer cells.…”

Section: Discussionmentioning

confidence: 99%

“…Acquired infiltrated and exfoliated erythroderma is another exceptional misleading occurrence 3. An associated skin cancer seems to have an increased risk of occurrence in sarcoidosis 4…”

Section: Introductionmentioning

confidence: 99%

Erythroderma with total scarring alopecia

et al. 2023

View full text Add to dashboard Cite

A woman in her 50s presented with total scarring ulcerated alopecia evolving for 10 years, and a recent budding tumour on the lower lip. Clinical examination revealed an associated exfoliated and infiltrated erythroderma with ulcerated cutaneous tumours of the legs, palmoplantar hyperkeratosis, hepatosplenomegaly and diffuse lymphadenopathies.Dermatoscopy of the scalp, leg tumours and infiltrated skin showed a typical yellowish background overlaid by arborescent vessels and whitish areas. Cutaneous biopsies of the same areas found sarcoidotic granulomas. Lip biopsy found an associated well-differentiated squamous cell carcinoma. Investigations confirmed the diagnosis of systemic sarcoidosis with an elevated converting enzyme level, mediastinal calcified lymphadenopathies in CT scan and deep localisations in positron emission tomography scan (thyroid, lymph nodes, mediastinum, liver, spleen and adrenal glands).The patient was treated with oral prednisone for sarcoidosis and intramuscular bleomycin followed by surgery and radiotherapy for squamous cell carcinoma. Sarcoidotic lesions healed, but a recurrence of her carcinoma led to death.

show abstract

“…In der bisherigen Forschung gab es dazu bereits einige Untersuchungen. Eine Kasuistik beschrieb einen Patienten, welcher ebenfalls ein faziales Plattenepithelkarzinom auf einer kutanen Sarkoidose entwickelte, jedoch zeigte sich in diesem Fall die Haut ohne Vorschädigung [6]. In einer Kohorte von 3 Personen trat diese Konstellation ebenfalls auf, die Plattenepithelkarzinome wurden ebenfalls chirurgisch exzidiert, bei 2 Patienten war wie in unserem Fall ein pulmonaler Befall der Sarkoidose festzustellen [7].…”

Section: Diskussionunclassified

“…Eine Abgrenzung zu unserem Fall ist, dass auch hier bei keinem Patienten eine physische Vorschädigung der Haut beschrieben wurde [7]. In beiden Darstellungen fand die Diagnostik allein anhand einer Gewebebiopsie statt [6,7].…”

Section: Diskussionunclassified

Drei auf einen Streich – Ein Plattenepithelkarzinom auf einem Lupus pernio und einer Erfrierung in nur einer Gesichtshälfte – ein Fallbericht

Mozaffari,

Fünfer,

Bader

et al. 2024

Aktuelle Dermatologie

View full text Add to dashboard Cite

ZusammenfassungAktuell gibt es keine Beschreibung eines kombinierten Auftretens von kutaner Sarkoidose, genauer eines Lupus pernio, einer durch Erfrierung vorgeschädigten Haut sowie eines Plattenepithelkarzinoms im selben Hautareal. Anhand unserer Kasuistik möchten wir einige Charakteristika der unterschiedlichen Effloreszenzen darstellen, hierbei auch anhand aktueller dermatologischer Bildgebungsverfahren wie der optischen Kohärenztomografie (OCT) und der Line-field konfokalen optischen Kohärenztomografie (LC-OCT). Durch die Evaluation des Patientenverlaufs möchten wir auf eine mögliche Inkludierung der Verfahren in die klinische Routine hinweisen, um sowohl Diagnostik als auch Therapie zu erleichtern. Da es sich um eine seltene Symptomkonstellation handelt, soll unsere Fallbeschreibung weiterhin den Therapieerfolg einer multimodalen topischen und systemischen Therapie verdeutlichen.

show abstract

Presentation of squamous cell carcinoma in pre-existing cutaneous sarcoidosis

Cited by 4 publications

References 7 publications

Development of thoracic sarcoid reactions associated with complete response to anti‐PD‐1 therapy in a patient with advanced cutaneous squamous cell carcinoma

Development of thoracic sarcoid reactions associated with complete response to anti‐PD‐1 therapy in a patient with advanced cutaneous squamous cell carcinoma

Erythroderma with total scarring alopecia

Drei auf einen Streich – Ein Plattenepithelkarzinom auf einem Lupus pernio und einer Erfrierung in nur einer Gesichtshälfte – ein Fallbericht

Contact Info

Product

Resources

About